GlaxoSmithKline may be suffering through a corruption scandal in China, but that hasn't interfered with its plans to team up with a Chinese company on vaccines. Its talks with potential partners are still on track, Christophe Weber, GSK's vaccines chief, told Bloomberg.
The French drugmaker is believed to have the lead candidate in the race for the badly needed vaccine and is making it known that it has started up production so it can have the potential blockbuster ready to go, assuming it gets approval in the next two years.
Alleged links between vaccines and the nerve-degenerative disorder Guillain-Barré are among vaccine safety fears. A new study shows that any link between them is not strong enough to outweigh the benefits of vaccines.
The experimental immunization stopped working in children by the fourth year after administration, a new study found.
Merck and GlaxoSmithKline have some persuading to do. A growing share of U.S. parents say they won't vaccinate their daughters against human papillomavirus, which causes cervical cancer. And that leaves Merck's Gardasil and GSK's Cervarix with a shrinking market.
The World Health Organization gave Indian vaccine makers a shot in the arm by approving the industry to supply vaccines to international bodies such as it and UNICEF.
HIV patients rely on a bevy of drugs to keep their illness under control, sticking to a strict regimen to maintain health. But let's face it: Adherence is a challenge and drug side effects can be rough. Enter HIV therapeutic vaccines. Read more >>
A virus found in man's best friend may offer a platform for developing a potent human vaccine.
Novartis' struggling vaccine unit got a shot in the arm today when the European Medicines Agency (EMA) recommended for approval, Bexsero, its potential blockbuster vaccine for meningitis B.
Every flu season, doctors and pharmacists must stock up on the latest influenza vaccine to offer patients. Unlike other vaccines that provide decades worth of protection, the flu vaccine needs to be administered every year. But researchers are looking to change this.